Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

r suicidal ideation and there was no evidence of abuse dependence.

The Company is on track to submit a New Drug Application (NDA) for Contrave with the FDA in the first half of 2010.

About Orexigen® Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that offer multiple approaches to treating obesity. The Company's lead investigational product, Contrave®, has completed the COR clinical development program and is on track for a regulatory submission with the FDA in the first half of 2010. The Company's second obesity drug candidate, Empatic(TM) has completed Phase 2 trials. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the efficacy and safety of Empatic(TM) and Contrave®, the potential for, and timing of, proceeding to Phase 3 clinical trials for Empatic or filing an NDA for Contrave, the commercial and therapeutic potential of Empatic and Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, either product candidate. The inclusion of forward-looking statements
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... According to a new market ... (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - Global ... the global endoscopy devices market was valued at USD ... at a CAGR of 6.8% from 2013 to 2019, ... in 2019. Browse the full Endoscopy Devices Market ...
(Date:7/11/2014)... 11, 2014 Neurelis, Inc. ("Neurelis") today announced ... the option held by Biotie to purchase Neurelis, clearing ... NRL-1 (intranasal diazepam) for pediatric and adult epilepsy patients ... past year, Biotie has advanced the development program for ... pivotal clinical work required for NDA submission to the ...
(Date:7/10/2014)... CARLSBAD, Calif. , July 10, 2014 /PRNewswire/ ... products and services, has launched the FreeRunner™ knee ... runners, who suffer from patella mal-tracking return to ... anatomy differently than other braces, providing support when ... move normally when they don,t. Patellofemoral ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... , Group Net LLC and Horizon Relief,s 1000 Bottles of Hope Work Together to ... , , ... Group Net LLC, a health care service company specializing in prescription medication and ... financial relief to those affected by the oil spill. , ...
... June 18 Novavax, Inc. (Nasdaq: NVAX ) ... Singhvi , President and Chief Executive Officer, will be presenting ... June 21 and June 22, 2010 at ... participating in the roundtable discussion, , Getting ready for the ...
Cached Medicine Technology:Health Care Organization Donates Funds to Gulf Coast Relief Organization 2Health Care Organization Donates Funds to Gulf Coast Relief Organization 3Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010 2
(Date:7/11/2014)... Europe is one of the largest ... hence, irrigated land area. The agricultural sector is a ... around 30.0% of the total water use. The scale ... southern region, but far from negligible in most northern ... over 60.0% of the water use in most countries, ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... best available treatment for patients, from a range of ... taxpayers than the existing clinical trial process, a new ... out while he was a member of the Clinical ... at The University of Manchester,s Health eResearch Centre, published ... today (Friday 11 July) looked at the use of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Experience Mayan ... Mayan Heritage Experience Package at the luxury all-inclusive AAA ... package include a guided on-site ecological family tour where ... as The Coba Mayan Encounter Tour at the Mayan ... Muul, the tallest pyramid in the Yucatan and the ...
(Date:7/11/2014)... 2014 WWTrek Human Outreach Project ... Community in Tanzania. Opened in 2012, the KKC is now ... cows. HOP Founder, Dean Cardinale, started the KKC to create ... orphaned children he encountered while running treks on Tanzania's Mount ... who have all made astounding progress in school over the ...
Breaking Medicine News(10 mins):Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3Health News:Human Outreach Project Sees Incredible Progress in the Kilimanjaro Kids Community 2
... scientists, led by researchers at the University of California, San ... for a condition in which eye and brain development is ... potential remedy that would involve a simple, daily dietary supplement. ... of glycosylation or CDG, a group of syndromes in which ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... does raise the risk of heart attack more than other ... with tightened controls, a U.S. government advisory panel recommended late ... panel of experts rejected the option that the U.S. Food ...
... from the American Cancer Society and other world-leading health ... whose potential to cause cancer is as yet unresolved. ... research, and to lead to well-planned epidemiologic or mechanistic ... The report, "Identification of research needs to resolve ...
... University researchers and African colleagues will be studying strategies ... and environmental health. The work in regions where the ... a $2.2 million, four-year grant from the U.S. National ... 24 villages in the Mvomero district of Tanzania to ...
... Winston Salem, N.C. New research accepted by the ... developed at Wake Forest University will slash years off the ... treatments to patients much more quickly. Lab-on-Bead uses ... a disease marker in a single step, so researchers can ...
... fight as soldiers in 86 countries across the globe, ... explored how these children adjust after they return to ... was the characteristics of the communities to which the ... that former child soldiers from Sierra Leone who lived ...
Cached Medicine News:Health News:UC San Diego researchers find cause of metabolic disease -- and possible cure 2Health News:UC San Diego researchers find cause of metabolic disease -- and possible cure 3Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 2Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 3Health News:Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds 4Health News:Report outlines knowledge gaps for 20 suspected carcinogens 2Health News:Duke and African partners to study sustainable malaria control 2Health News:Researchers cut years from drug development with nanoscopic bead technology 2Health News:Studies explore effects of war on former child soldiers 2Health News:Studies explore effects of war on former child soldiers 3Health News:Studies explore effects of war on former child soldiers 4
A budget-priced microscope designed for ENT and neuro surgery....
... has pioneered the development of ... system, an innovative solution that ... efficient and less invasive. The ... the OME-7000 surgical microscope, the ...
... Leica M501 TTS offers the comfort of ... and training application. The microscope offers brilliant ... stereopsis and natural color reproduction. A separate ... can be optimized with a special jalousie ...
The Leica M500 OH3 is an advanced surgical microscope used by neurosurgeons. It is a smart system combining the best optical performance available on the market with an innovative and unique stand....
Medicine Products: